Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eyepoint Pharmaceuticals Inc (NQ: EYPT )

11.59 -0.49 (-4.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eyepoint Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
EyePoint Pharma Posts 12-Month Safety, Efficacy Data From Early-Stage Wet AMD Trial
Via Benzinga
Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock
Via Benzinga
NASDAQ:EYPT Investor Alert: Investigation over Potential Securities Laws Violations by EyePoint Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 11/02/2022 -- EyePoint Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
EyePoint Pharmaceuticals: Q3 Earnings Insights
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Vintage Wine, Flowserve, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating FedEx, Cantaloupe, Compass, and EyePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, F45 Training, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Meet The Company Bringing New Treatments For Serious Eye Issues To Market
Sign up for this week’s All Access giveaway here! 
Via Benzinga
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: EyePoint Pharmaceuticals Q2 Earnings
  EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Preview For EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a... 
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
7 Wildly Oversold Nasdaq Stocks to Buy Now
For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.